Adebrelimab and Chidamide for Pancreatic Cancer

Pancreatic cancer is a kind of digestive system tumor with high malignant degree and poor prognosis. Most patients with pancreatic cancer are locally advanced or have distant metastases at the time of diagnosis, so it is extremely important to find effective drugs to control tumor metastasis. The primary treatment regimen for advanced pancreatic cancer remains chemotherapy, which results in a median survival time of only 8 to 12 months. Therefore, there is an urgent need to explore new combination therapies to extend survival. Therefore, this study aims to evaluate the efficacy and safety of A

Trial Details

NCT ID
NCT06584227
Phase
PHASE2
Sponsor
Liu Xiufeng
Status
RECRUITING
Cancer Type
Pancreatic Cancer
Interventions
  • Adebrelimab and Chidamide Combined with Gemcitabine and S1
Locations (sample)
  • Nanjing, Jiangsu, China|32.06167,118.77778

Key Eligibility Criteria

  • 18 to 75 years old;
  • Histologically or cytologically confirmed pancreatic cancer (originating from the ductal epithelium of the pancreas) with clinically documented unr…
  • have not previously received systematic antitumor therapy for the current stage of disease, including surgery (except stent placement), radiotherap…
  • There must be at least one measurable lesion as a target lesion (according to RECIST v1.1 standards);

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Cancer Trials on Trialify →